GRAIL, Inc. (Nasdaq: GRAL), a healthcare company focused on early cancer detection, has announced a new partnership with athenahealth, a prominent provider of healthcare software solutions. This collaboration aims to integrate the ordering of GRAIL's Galleri® multi-cancer early detection (MCED) test into athenaCoordinator Core, part of athenahealth's cloud-based electronic health record (EHR) system. This integration will enable over 160,000 U.S. clinicians on the athenahealth network to more efficiently order the Galleri test, streamlining the process and reducing administrative burdens. The Galleri test, which screens for multiple cancers through a single blood draw, will help enhance routine exams and improve access to early cancer detection for patients at elevated risk.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.